BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

1. Truist initiated coverage on BioNTech, rating it a Buy with $172 target. 2. BNT327 could surpass $42 billion PD-1 category by 2023 with strong sales. 3. BioNTech's oncology focus strengthens with acquisition of Biotheus for innovative antibodies. 4. Key data updates expected in 2025 may enhance investor perception of BNTX. 5. COVID-19 developments still significantly impact BioNTech's stock performance.